CAR-NK Cells (CL-NK-001) in Pancreatic Cancer
This is a single-center, open-label, first-in-human, dose-escalation study in patients with pancreatic cancer.
Pancreatic Cancer
BIOLOGICAL: CL-NK-001
Dose-limiting toxicity (DLT), Safety, 42 days of first infusion|Maximum tolerated dose (MTD), Tolerability, 42 days of first infusion|Treatment-emergent adverse event (TEAE) and treatment-emergent serious adverse event (TESAE), Safety, 42 days of first infusion|Number of participants with abnormal clinical laboratory parameters reported as TEAE, Safety, 42 days of first infusion|Number of participants with abnormal vital signs reported as TEAE, Safety, 42 days of first infusion|Number of participants with change from baseline in QT/QTc interval in electrocardiogram, Safety, 42 days of first infusion
Objective response rate (ORR), Efficacy, 42 days of first infusion|Disease control rate (DCR), Efficacy, 42 days of first infusion|Progression-free survival (PFS), Efficacy, 6 months|Overall survival (OS), Efficacy, 6 months|Patient-reported quality of life (QoL), Measured by the European Organization for Research and Treatment of Cancer quality-of-life questionnaire (EORTC QLQ-C30), 42 days of first infusion|Patient-generated subjective global assessment (PG-SGA), Nutritional status measurement with a medical history section assessed by patients and a physical assessment section assessed by medical staff, 42 days of first infusion
A dose-escalation study will evaluate the safety, tolerability and efficacy of CAR-NK cells (CL-NK-001) in patients with locally advanced, metastatic, or recurrent pancreatic cancer.